The maximum tolerated dose of tirzepatide was administered during the study, and the safety profile observed was consistent with that previously reported in the SURMOUNT and SURPASS trials, as well as studies of incretin-based therapies approved for the treatment of obesity and overweight [38,66]. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.